Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Completed
377 enrolled
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Recruiting
1,100 enrolled
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2 Recruiting
332 enrolled
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Phase 1/2 Recruiting
124 enrolled
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
Completed
40 enrolled
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase 1 Completed
40 enrolled
Non-Viral TCR Gene Therapy
Phase 2 Withdrawn
A Follow-up Study of Women Evaluated and Treated for Infertility
Completed
12,193 enrolled
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
Completed
1,031 enrolled
A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer
Phase 2 Terminated
111 enrolled 15 charts
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
Phase 1/2 Completed
21 enrolled 22 charts
Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
Phase 1 Completed
38 enrolled 20 charts
Continuation of Follow-up of DES-Exposed Cohorts
Completed
10,805 enrolled
Extended Follow-up of Columbia, MO Serum Bank Participants
Completed
6,720 enrolled
Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
Completed
6,086 enrolled
Bone Mineral Density and Subsequent Cancer Risk
Completed
15,595 enrolled
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers
Phase 1 Completed
77 enrolled
Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer
Phase 2 Terminated
1 enrolled 7 charts
Methods in Education for Breast Cancer Genetics
Phase 3 Completed
170 enrolled
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
Terminated
8 enrolled
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Phase 1 Completed
103 enrolled
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
Phase 1/2 Terminated
3 enrolled 14 charts
PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
Phase 1/2 Completed
51 enrolled 20 charts
TKM 080301 for Primary or Secondary Liver Cancer
Phase 1 Completed
1 enrolled
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy
Phase 1 Completed
98 enrolled
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Phase 1 Completed
45 enrolled
Microarray Analysis for Human Genetic Disease
Completed
1,500 enrolled
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Phase 1 Withdrawn
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer
Phase 1/2 Completed
45 enrolled 8 charts
Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation
Phase NA Completed
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
20 enrolled
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
Phase 1 Completed
68 enrolled
Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections
Phase 1 Unknown
20 enrolled
High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
Phase 1/2 Unknown
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
Phase 1 Completed
41 enrolled
Carboplatin or Docetaxel in Treating Women With Metastatic Genetic Breast Cancer
Phase 2 Completed
148 enrolled
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer
Phase NA Unknown
2,200 enrolled
Early Detection of Breast Cancer and Cervical Cancer in Women in India
Phase 2 Unknown
151,538 enrolled
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Phase 2 Unknown
60 enrolled
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
Phase 3 Completed
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase 1 Completed
18 enrolled
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Phase 1 Completed
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
Phase 1 Completed
28 enrolled
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
Phase 1 Completed
30 enrolled
Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
Phase 1 Completed
21 enrolled
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled